An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Canopy Biosciences Launches Next-Generation ChipCytometry™ Instrument for Spatial Biology with Sub-Cellular Resolution
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Canopy Biosciences, a Bruker Company, launched the CellScape™ System, enhancing ChipCytometry technology for high-plex spatial proteomics. This new benchtop system improves automation, optical performance, and throughput, enabling researchers to analyze millions of cells with single-cell resolution. Since the 2020 acquisition by Bruker, Canopy has advanced its capabilities, setting a new standard in spatial biology research. The CellScape™ is designed for large-scale clinical studies and is compatible with standard fluorescently labeled antibodies, fostering streamlined workflows in immunology and other fields.
Positive
Launch of the new CellScape™ system enhances capabilities in spatial biology.
Significantly improved automation and throughput for analyzing millions of cells.
Compatible with standard fluorescent antibodies, no proprietary conjugation required.
Opportunity for larger clinical studies due to increased throughput.
Negative
None.
New CellScape™ System Provides Exceptional Quantitative Performance for High-Plex and High-Throughput Targeted Spatial Proteomics
ST. LOUIS--(BUSINESS WIRE)--
Canopy Biosciences, a Bruker Company, today announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease.
CellScape instrument for high-plex, targeted spatial proteomics. (Photo: Business Wire)
The new benchtop CellScape system builds on the existing core strengths of the original ChipCytometry instrument, the ZellScannerONE™, which has enabled spatial biology research with sub-cellular resolution and a large field of view suitable for whole slide pathology imaging, on both tissue samples and cell suspensions since 2016. The CellScape system , with its multiplexed fluidics integration, adds complete walk-away automation, improved optical performance, sub-cellular resolution and massively increased throughput for whole slide imaging of millions of cells, while maintaining the key features of the core ChipCytometry technology, including high-plex phenotyping with single-cell resolution, very high dynamic range imaging for detection and quantification of both high- and low-expressing targets, and compatibility with standard commercially available fluorescently labelled antibodies, requiring no proprietary antibody conjugation. This powerful combination of features will significantly improve researchers’ workflow, accelerate spatial biology discovery, and drive broader adoption of high-plex spatial omics for translational and clinical applications.
“The ChipCytometry platform has been a great tool for us in developing high content staining approaches for in-depth spatial immune profiling of human tissue samples,” said Paul Klenerman, Ph.D., Professor of Gastroenterology at The University of Oxford. “The improvements to throughput and automation of the CellScape system gives the opportunity to scale up studies and explore larger cohorts – and accelerate studies aimed at improving patient care.”
“Following the acquisition of Canopy Biosciences by Bruker in 2020, we were able to leverage Bruker’s advanced fluorescence microscopy expertise to design the CellScape instrument as an integrated, multiplexed imaging system that is highly optimized for the application of high-throughput quantitative spatial omics with sub-cellular resolution,” added Thomas Campbell, Ph.D., Product Manager at Canopy Biosciences. “The improved optical performance of the system builds on the high resolution and high dynamic range that was already best-in-class with our ChipCytometry technology.”
About the CellScapeInstrument
Through enhanced optics and automation, the throughput of CellScape is markedly improved compared to the previous generation of ChipCytometry instrumentation. Combined with multi-sample automated processing, which is available standard with every CellScape, the platform will have among the highest throughput of any highly multiplexed spatial proteomics system available today. CellScape will also be available with an optional FalconFastTM configuration, which provides an even greater increase in throughput, bringing into reach large-scale clinical studies that have previously not been possible at a high plex. For more information about CellScape, visit www.CanopyBiosciences.com/CellScape.
About Canopy Biosciences, a Bruker Company
Canopy Biosciences was formed in 2016 and rapidly built a comprehensive portfolio of products and services for spatial biology, multi-omics, and bioprocessing. Canopy offers its ChipCytometry technology for precise spatial multiplexing in cells and tissue samples, along with other technologies of ultrasensitive DNA sequencing (RareSeq), RNA-Seq, and gene expression analysis for services. Canopy Biosciences is headquartered in St. Louis, Missouri, with a CLIA site in California, and a site in Germany to serve researchers at universities, research institutions, and biotechnology and pharmaceutical companies worldwide. Canopy was acquired by Bruker Corporation (Nasdaq: BRKR) in 2020. Additional information is available at www.canopybiosciences.com.
Media:
Kevin Gamber Vice President, Marketing
Canopy Biosciences, a Bruker Company T: +1 (314) 662-9987
E: kevin.gamber@bruker.com
Source: Bruker Corporation
FAQ
What is the CellScape™ system launched by Bruker?
The CellScape™ system is a new technology for high-plex spatial proteomics that enhances the capabilities of the existing ChipCytometry platform.
How does the CellScape™ system improve research workflows?
It offers improved automation, optical performance, and significantly higher throughput, allowing for the analysis of millions of cells.
What applications can benefit from the CellScape™ system?
The system is ideal for spatial biology applications in immunology, neuroscience, and infectious disease.
When was Canopy Biosciences acquired by Bruker?
Canopy Biosciences was acquired by Bruker in 2020.
What are the key features of the CellScape™ system?
Key features include single-cell resolution, high-plex phenotyping, enhanced optical performance, and compatibility with standard fluorescent antibodies.
